A double-blind, placebo-controlled randomized trial of vilazodone in the treatment of posttraumatic stress disorder and comorbid depression

Sriram Ramaswamy, David Driscoll, Christopher Reist, Lynette M. Smith, Lawrence J. Albers, Jodette Rose, Linda Nguyen, Varun Monga, Ryan Doria, Michael Hollifield

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Objective: To determine the efficacy, safety, and tolerability of vilazodone in the treatment of posttraumatic stress disorder (PTSD) with comorbid mild-to-moderate depression. Methods: A 12-week randomized, double-blind, placebo-controlled trial was conducted in adult outpatients who met DSM-IV criteria for PTSD with comorbid depression between February 2013 and September 2015. Participants were randomly assigned to receive vilazodone 40 mg/d or placebo, and outcome measures were obtained at scheduled visits. Primary outcome measures included change in PTSD symptoms from baseline to end of study as indexed by the Clinician-Administered PTSD Scale (CAPS) and PTSD Symptom Scale-Self-Report (PSS-SR). Secondary outcome measures of anxiety, depression, and impairment were obtained, as well as biomarker assessment at baseline and end of study. Results: A total of 59 patients were randomly assigned to receive vilazodone (n = 29) or placebo (n = 30). Of those who were randomized, there were 25 completers in the vilazodone group and 22 completers in the placebo group. No significant differences were observed between the groups on any of the primary or secondary outcome measures. Vilazodone was generally well tolerated with few differences in the rate of adverse events between groups. Conclusions: Treatment with vilazodone 40 mg/d did not improve symptoms of PTSD and comorbid depression. Further investigation of the biological mechanisms underlying PTSD may lead to identification of improved therapeutic targets.

Original languageEnglish (US)
Article number17m02138
JournalPrimary Care Companion to the Journal of Clinical Psychiatry
Volume19
Issue number4
DOIs
StatePublished - 2017

Fingerprint

Post-Traumatic Stress Disorders
Randomized Controlled Trials
Placebos
Depression
Outcome Assessment (Health Care)
Therapeutics
compound A 12
Vilazodone Hydrochloride
Diagnostic and Statistical Manual of Mental Disorders
Self Report
Outpatients
Anxiety
Biomarkers
Safety

All Science Journal Classification (ASJC) codes

  • Psychiatry and Mental health

Cite this

A double-blind, placebo-controlled randomized trial of vilazodone in the treatment of posttraumatic stress disorder and comorbid depression. / Ramaswamy, Sriram; Driscoll, David; Reist, Christopher; Smith, Lynette M.; Albers, Lawrence J.; Rose, Jodette; Nguyen, Linda; Monga, Varun; Doria, Ryan; Hollifield, Michael.

In: Primary Care Companion to the Journal of Clinical Psychiatry, Vol. 19, No. 4, 17m02138, 2017.

Research output: Contribution to journalArticle

Ramaswamy, Sriram ; Driscoll, David ; Reist, Christopher ; Smith, Lynette M. ; Albers, Lawrence J. ; Rose, Jodette ; Nguyen, Linda ; Monga, Varun ; Doria, Ryan ; Hollifield, Michael. / A double-blind, placebo-controlled randomized trial of vilazodone in the treatment of posttraumatic stress disorder and comorbid depression. In: Primary Care Companion to the Journal of Clinical Psychiatry. 2017 ; Vol. 19, No. 4.
@article{9fca348fea1b465b80152ecf7e53e361,
title = "A double-blind, placebo-controlled randomized trial of vilazodone in the treatment of posttraumatic stress disorder and comorbid depression",
abstract = "Objective: To determine the efficacy, safety, and tolerability of vilazodone in the treatment of posttraumatic stress disorder (PTSD) with comorbid mild-to-moderate depression. Methods: A 12-week randomized, double-blind, placebo-controlled trial was conducted in adult outpatients who met DSM-IV criteria for PTSD with comorbid depression between February 2013 and September 2015. Participants were randomly assigned to receive vilazodone 40 mg/d or placebo, and outcome measures were obtained at scheduled visits. Primary outcome measures included change in PTSD symptoms from baseline to end of study as indexed by the Clinician-Administered PTSD Scale (CAPS) and PTSD Symptom Scale-Self-Report (PSS-SR). Secondary outcome measures of anxiety, depression, and impairment were obtained, as well as biomarker assessment at baseline and end of study. Results: A total of 59 patients were randomly assigned to receive vilazodone (n = 29) or placebo (n = 30). Of those who were randomized, there were 25 completers in the vilazodone group and 22 completers in the placebo group. No significant differences were observed between the groups on any of the primary or secondary outcome measures. Vilazodone was generally well tolerated with few differences in the rate of adverse events between groups. Conclusions: Treatment with vilazodone 40 mg/d did not improve symptoms of PTSD and comorbid depression. Further investigation of the biological mechanisms underlying PTSD may lead to identification of improved therapeutic targets.",
author = "Sriram Ramaswamy and David Driscoll and Christopher Reist and Smith, {Lynette M.} and Albers, {Lawrence J.} and Jodette Rose and Linda Nguyen and Varun Monga and Ryan Doria and Michael Hollifield",
year = "2017",
doi = "10.4088/PCC.17m02138",
language = "English (US)",
volume = "19",
journal = "The primary care companion for CNS disorders",
issn = "1523-5998",
publisher = "Physicians Postgraduate Press Inc.",
number = "4",

}

TY - JOUR

T1 - A double-blind, placebo-controlled randomized trial of vilazodone in the treatment of posttraumatic stress disorder and comorbid depression

AU - Ramaswamy, Sriram

AU - Driscoll, David

AU - Reist, Christopher

AU - Smith, Lynette M.

AU - Albers, Lawrence J.

AU - Rose, Jodette

AU - Nguyen, Linda

AU - Monga, Varun

AU - Doria, Ryan

AU - Hollifield, Michael

PY - 2017

Y1 - 2017

N2 - Objective: To determine the efficacy, safety, and tolerability of vilazodone in the treatment of posttraumatic stress disorder (PTSD) with comorbid mild-to-moderate depression. Methods: A 12-week randomized, double-blind, placebo-controlled trial was conducted in adult outpatients who met DSM-IV criteria for PTSD with comorbid depression between February 2013 and September 2015. Participants were randomly assigned to receive vilazodone 40 mg/d or placebo, and outcome measures were obtained at scheduled visits. Primary outcome measures included change in PTSD symptoms from baseline to end of study as indexed by the Clinician-Administered PTSD Scale (CAPS) and PTSD Symptom Scale-Self-Report (PSS-SR). Secondary outcome measures of anxiety, depression, and impairment were obtained, as well as biomarker assessment at baseline and end of study. Results: A total of 59 patients were randomly assigned to receive vilazodone (n = 29) or placebo (n = 30). Of those who were randomized, there were 25 completers in the vilazodone group and 22 completers in the placebo group. No significant differences were observed between the groups on any of the primary or secondary outcome measures. Vilazodone was generally well tolerated with few differences in the rate of adverse events between groups. Conclusions: Treatment with vilazodone 40 mg/d did not improve symptoms of PTSD and comorbid depression. Further investigation of the biological mechanisms underlying PTSD may lead to identification of improved therapeutic targets.

AB - Objective: To determine the efficacy, safety, and tolerability of vilazodone in the treatment of posttraumatic stress disorder (PTSD) with comorbid mild-to-moderate depression. Methods: A 12-week randomized, double-blind, placebo-controlled trial was conducted in adult outpatients who met DSM-IV criteria for PTSD with comorbid depression between February 2013 and September 2015. Participants were randomly assigned to receive vilazodone 40 mg/d or placebo, and outcome measures were obtained at scheduled visits. Primary outcome measures included change in PTSD symptoms from baseline to end of study as indexed by the Clinician-Administered PTSD Scale (CAPS) and PTSD Symptom Scale-Self-Report (PSS-SR). Secondary outcome measures of anxiety, depression, and impairment were obtained, as well as biomarker assessment at baseline and end of study. Results: A total of 59 patients were randomly assigned to receive vilazodone (n = 29) or placebo (n = 30). Of those who were randomized, there were 25 completers in the vilazodone group and 22 completers in the placebo group. No significant differences were observed between the groups on any of the primary or secondary outcome measures. Vilazodone was generally well tolerated with few differences in the rate of adverse events between groups. Conclusions: Treatment with vilazodone 40 mg/d did not improve symptoms of PTSD and comorbid depression. Further investigation of the biological mechanisms underlying PTSD may lead to identification of improved therapeutic targets.

UR - http://www.scopus.com/inward/record.url?scp=85030318844&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85030318844&partnerID=8YFLogxK

U2 - 10.4088/PCC.17m02138

DO - 10.4088/PCC.17m02138

M3 - Article

C2 - 28858440

AN - SCOPUS:85030318844

VL - 19

JO - The primary care companion for CNS disorders

JF - The primary care companion for CNS disorders

SN - 1523-5998

IS - 4

M1 - 17m02138

ER -